IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 2384 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
 
ORIGINAL ARTICLE
Ahead of Print

A randomized, double-blind trial of amorolfine 0.25% cream and sertaconazole 2% cream in limited dermatophytosis


1 Department of Dermatology, Murshidabad Medical College and Hospital, Berhampore, West Bengal, India
2 Department of Pharmacology, Rampurhat Government Medical College, Rampurhat, West Bengal, India
3 Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India
4 Department of Microbiology, Medical College and Hospital, Kolkata, West Bengal, India
5 Department of Biochemistry, Medical College and Hospital, Kolkata, West Bengal, India
6 Department of Dermatology, Bankura Sammilani Medical College, Bankura, West Bengal, India

Correspondence Address:
Amrita Sil,
Flat 3I, Block 4, 83A Cossipore Road, Kolkata - 700 002, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijdvl.IJDVL_907_17

PMID: 30409926

Background: Dermatophytosis is becoming increasingly unresponsive to conventional antifungals. Newer topical antifungals may be more effective in these patients. Aims: To evaluate and compare the efficacy and safety of amorolfine 0.25% cream and sertaconazole 2% cream in limited tinea cruris/corporis. Methods: A single-center, randomized (1:1), double-blind, parallel group, active-controlled trial (CTRI/2014/12/005246) was performed. Sixty-six untreated adults with acutely symptomatic tinea cruris/corporis were included in the study. All patients had limited cutaneous involvement and were KOH mount positive. Group A received amorolfine 0.25% cream, and group B received sertaconazole 2% cream twice daily application to the lesions for 4 weeks. After the baseline visit, four follow-up visits were carried out. The outcome measures for effectiveness were clinical and mycological cure. Safety parameters studied were treatment-emergent adverse events and changes in routine laboratory parameters. Results: Both sertaconazole and amorolfine significantly reduced symptoms (P < 0.001) in both groups. However, improvement in symptoms (pruritus, burning sensation, erythema, scaling and crusting) was significantly greater in the sertaconazole group at every follow-up visit. Sertaconazole cream was also more effective than amorolfine cream in reducing the number of lesions (P = 0.002 at 12 weeks) and improving the Dermatology Life Quality Index (P < 0.001) at all the follow-up visits. Adverse events were similar in the two groups (P = 0.117). Fungal cultures became negative in 92.3% of the sertaconazole group as compared to 80% in the amorolfine group (P = 0.010). Limitations: Antifungal susceptibility testing could not be done. Conclusion: Sertaconazole 2% is superior to amorolfine 0.25%, both in terms of effectiveness and tolerability. Improvement can be appreciated from second week onwards.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Das A
    -  Sil A
    -  Sarkar TK
    -  Sen A
    -  Chakravorty S
    -  Sengupta M
    -  Das A
    -  Chandra S
    -  Pal S
    -  Bandyopadhyay D
    -  Das NK
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed119    
    PDF Downloaded18    

Recommend this journal

Online since 15th March '04
Published by Wolters Kluwer - Medknow